EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC
Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
Video content above is prompted by the following:
- How does histology, staging and ECOG performance status play into treatment considerations at your practice today, and how do these factors compare to the baseline characteristics of this study?
- What other biomarkers, if any, are important in determining the efficacy of PD-1 inhibitors like cemiplimab before initiating therapy, both in NSCLC and for other indications?
- Overall, how does this patient population compare with those treated in 2025 with immune checkpoint inhibitors or other first-line treatment options for advanced NSCLC?
Combining Avastin With Alecensa Shows Promise in Advanced ALK-Positive Lung Cancer
May 29th 2025A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain metastases, and improved quality of life in patients with advanced ALK-positive lung cancer.
Read More
ICI-Chemo Combo Delivers More Benefit Than Harm, Even for High-Risk NSCLC Patients, Study Finds
May 16th 2025Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.
Read More
Time Well Spent: Lung Cancer Trials Offer Improved Survival Without Added Burden
May 7th 2025Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.
Read More
